NCT02649673 2023-12-05
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Terminated
Clinical Trials
10 trialsNCT02098161 2023-06-06
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT03111992 2022-02-09
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Novartis
Phase 1 Completed
NCT01240655 2020-12-19
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01968915 2020-12-19
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01955434 2019-09-10
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01617668 2016-10-17
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Novartis
Phase 2 Completed
NCT01934634 2015-11-10
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
US Oncology Research
Phase 1 Unknown
NCT01098838 2012-08-03
Safety and Efficacy of LCL161 in Patients With Solid Tumors
Novartis
Phase 1 Completed